DUPONT CAPITAL MANAGEMENT CORP - REPLIGEN CORP ownership

REPLIGEN CORP's ticker is RGEN and the CUSIP is 759916109. A total of 438 filers reported holding REPLIGEN CORP in Q4 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
DUPONT CAPITAL MANAGEMENT CORP ownership history of REPLIGEN CORP
ValueSharesWeighting
Q2 2023$582,532
-22.1%
4,118
-7.3%
0.03%
-19.4%
Q1 2023$747,687
-16.5%
4,441
-16.1%
0.04%
-14.3%
Q4 2022$895,819
-15.9%
5,291
-7.0%
0.04%
-33.3%
Q3 2022$1,065,000
-2.8%
5,692
-15.6%
0.06%
+23.5%
Q2 2022$1,096,000
+13.1%
6,748
+30.9%
0.05%
+30.8%
Q1 2022$969,000
-49.1%
5,154
-28.3%
0.04%
-42.6%
Q4 2021$1,904,000
-15.5%
7,190
-7.8%
0.07%
-4.2%
Q3 2021$2,254,000
+249.5%
7,800
+141.3%
0.07%
+373.3%
Q2 2021$645,000
+2.5%
3,2330.0%0.02%0.0%
Q1 2021$629,000
-11.9%
3,233
-13.3%
0.02%0.0%
Q4 2020$714,000
+29.8%
3,7270.0%0.02%
+25.0%
Q3 2020$550,000
+7.0%
3,727
-10.3%
0.01%
+9.1%
Q2 2020$514,000
+27.5%
4,155
-0.6%
0.01%
+10.0%
Q1 2020$403,000
-48.9%
4,179
-51.0%
0.01%
-44.4%
Q4 2019$789,000
+101.8%
8,528
+67.2%
0.02%
+100.0%
Q3 2019$391,000
-9.3%
5,100
-64.1%
0.01%
+12.5%
Q1 2015$431,000
+56.7%
14,202
+2.2%
0.01%
+60.0%
Q4 2014$275,000
-69.3%
13,892
-69.2%
0.01%
-68.8%
Q3 2014$897,000
-12.6%
45,0320.0%0.02%
-5.9%
Q2 2014$1,026,000
+77.2%
45,0320.0%0.02%
+88.9%
Q1 2014$579,000
-5.7%
45,0320.0%0.01%
-18.2%
Q4 2013$614,00045,0320.01%
Other shareholders
REPLIGEN CORP shareholders Q4 2022
NameSharesValueWeighting ↓
Conestoga Capital Advisors, LLC 1,291,805$53,532,0002.79%
Ranger Investment Management 919,366$38,099,0002.72%
Monashee Investment Management LLC 100,000$4,144,0001.75%
Lisanti Capital Growth, LLC 49,450$2,049,0001.36%
Pier Capital, LLC 175,565$7,275,0001.26%
SANDLER CAPITAL MANAGEMENT 221,070$9,161,0000.99%
PALISADE CAPITAL MANAGEMENT, LP 630,333$26,121,0000.98%
AWM Investment Company, Inc. 120,000$4,973,0000.88%
Stephens Investment Management Group LLC 857,714$35,544,0000.86%
Summit Creek Advisors LLC 79,066$3,276,0000.68%
View complete list of REPLIGEN CORP shareholders